Compositions and methods for systemic delivery of at least one cargo in a vascular plant. Compositions may include at least one cargo delivery particle, having a core and a shell; and at least one cargo disposed on the shell. The core may include at least one micronutrient. The shell may include a coating material. The at least one cargo delivery particle may have a size of less than about 10 nanometers. Methods may include administering an effective amount of the compositions to a plant.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Compositions containing iron, buffering agent and denatured protein have been prepared that are capable of increasing serum iron in a subject. For example, spray dried microbeads have been prepared containing iron entrapped within a protein matrix and unbound iron in a buffered composition that provides a gastroprotective effect, preserves iron in the more available Fe.sup.2+ form and improves iron bioavailability in humans relative to previously known vehicles for delivering iron to a subject.

An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein. Also provided are methods for making and using the enteric-coated oral dosage form. The disclosed pharmaceutical compositions comprise an enteric coating which includes at least one plasticizer, at least one film-forming agent and optionally at least one anti-sticking agent.

Self-assembled organic ligand functionalized microcapsules encapsulating one or more substrates, which release the substrates upon activation with a power source, are provided. Compositions that include these microcapsules, as well as methods of making the microcapsules and releasing the encapsulated substrates are also provided. The structures, compositions and methods find use in a variety of applications, such as drug and cell encapsulation technologies, for direct delivery, control, and activation of medicines and therapies to specific tissues in a living host.

A core-shell structure (1) comprising a core (2) of titanium oxide and a shell (3) essentially comprising, preferably consisting, of an oxide of an element selected from a group consisting of zinc, copper, vanadium, chromium, manganese, cobalt, molybdenum, tungsten, silver and mixtures thereof. A method for making a core-shell structure, in particular a core-shell structure (1) as described above, and the use of a plurality of such core-shell structures (1) as a food additive, a feed additive, in a feed stuff or as a medicament.

Disclosed are biodegradable core-shell microcapsule compositions composed of microcapsules having a wall formed by self-condensation of an isocyanate in the presence of a denatured pea protein as dispersant. Also disclosed are consumer products containing such a core-shell microcapsule composition and methods for producing core-shell microcapsule compositions.

The disclosure features methods for treating ovarian cancer, as well as other cancers such as solid tumors, lymphomas and epithelial origin cancers, by administering mRNA encoding an OX40L polypeptide. The disclosure also features compositions for use in the methods. The disclosure also features combination therapies, such as use of mRNA encoding an OX40L polypeptide in combination with a checkpoint inhibitor, such as an anti-PD-L1 antibody.

Improved methods and compositions are disclosed for treating dry eye by administering intranasally a therapeutically effective amount of a capsaicinoid compound embedded in multiple layers of solid lamellar crystals of monoglycerides to patients with deficient tear production. The lipophilic capsaicinoid drug is embedded in multiple layers of solid lamellar crystals of monoglycerides, and these crystals are incorporated into pharmaceutically acceptable vehicles comprised of solutions, suspensions, foams, creams, ointments, and gels. The resulting formulations of the capsaicinoid are more stable, less irritating to skin and mucous membranes, and provide increased and more controlled release of the capsaicinoid compound.

Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising Ibuprofen using solventless mixing methods. Excess coating material that is not bound to coated Ibuprofen may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Additionally, the compositions can be formulated to preserve the functional coating of coated Ibuprofen and to minimize aeration of Ibuprofen when mixed into suspension.